接受尼塞韦单抗婴儿的呼吸道合胞病毒相关住院情况
该检测阴性病例对照研究纳入安大略省和魁北克省7家三级儿科医院中<12月龄、因症状检测RSV的婴儿,2024年10月27日至2025年3月1日共1942次就诊。683例RSV阳性(病例),1259例阴性(对照),22.1%接受过尼塞韦单抗。调整后尼塞韦单抗对实验室确诊RSV感染有效性78%(95%CI 68%-84%),对ED就诊77%、住院79%、ICU入住97%。结论提示尼塞韦单抗对需医院救治的RSV疾病有高估计有效性。
要点
- 对<12月龄有症状并检测RSV的婴儿,尼塞韦单抗对实验室确诊RSV感染调整后有效性78%(95%CI 68%-84%)。
- 分层结局:对ED就诊有效性77%(95%CI 62%-86%),对住院79%(95%CI 66%-87%),对ICU入住97%(95%CI 85%-100%)。
- 早产儿亚组有效性90%(95%CI 66%-98%),有合并症婴儿86%(95%CI 37%-98%)。
- 接种后时间亚组有效性85%(95%CI 75%-92%),敏感性分析与主分析一致。
- 病例组接受尼塞韦单抗比例7.0%(48/683)低于对照组30.3%(381/1259),P<.001。
适用人群与场景
- 加拿大安大略省和魁北克省7家三级儿科医院(SPRINT-KIDS项目成员)中,2024年10月27日至2025年3月1日因症状在ED、住院部或ICU检测RSV的<12月龄婴儿。
- 纳入1942次合格就诊,中位年龄3.0月(IQR 1.9-5.6),男性1110例(57.2%)。
- 暴露定义为RSV检测日期前≥7天接受尼塞韦单抗。
诊断标准与关键阈值
- 主要结局为实验室确诊RSV感染;按标本采集当日或随后14天内的处置结局分层:仅ED就诊、住院、ICU入住。
- 检测阴性病例对照设计:RSV阳性为病例,RSV阴性为对照。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:检测阴性病例对照研究,7家三级儿科医院,1942次婴儿就诊。
- 1942次就诊中683次(35.2%)RSV阳性为病例,1259次(64.8%)阴性为对照;429例(22.1%)接受尼塞韦单抗。
- 病例组接受尼塞韦单抗48/683(7.0%),对照组381/1259(30.3%),P<.001。
- 调整后尼塞韦单抗对实验室确诊RSV感染有效性78%(95%CI 68%-84%)。
- 对ED就诊有效性77%(95%CI 62%-86%),对住院79%(95%CI 66%-87%),对ICU入住97%(95%CI 85%-100%)。
- 亚组:早产儿90%(95%CI 66%-98%),有合并症86%(95%CI 37%-98%),接种后时间85%(95%CI 75%-92%)。
- 敏感性分析与主分析结果一致。
证据类型、等级与局限
- 证据类型:检测阴性病例对照研究。
- 局限性:原文未明确列出局限性;设计本身为观察性、多中心但仅7家医院、仅在加拿大两省、单一季节。
对床旁实践的改变
- 支持对<12月龄婴儿使用尼塞韦单抗以降低需医院救治的RSV疾病负担,尤其对ICU入住估计有效性高(97%)。
- 对早产儿和有合并症婴儿亚组仍显示高估计有效性,但合并症亚组95%CI较宽(37%-98%),解释需谨慎。
- 该研究为观察性检测阴性设计,估计有效性不能等同于RCT疗效;不适用于无加拿大两省2024-2025季背景的其他人群或季节。
指南或共识出处
- 原文未提及指南或共识名称;研究由加拿大安大略省和魁北克省公共卫生资助尼塞韦单抗项目背景下的SPRINT-KIDS项目数据。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Respiratory syncytial virus (RSV) is a leading cause of hospitalization among infants. Nirsevimab, a long-acting monoclonal antibody that protects against severe RSV, was publicly funded for all infants in the Canadian provinces of Ontario and Quebec starting in the fall of 2024.
OBJECTIVE: To estimate the clinical effectiveness of nirsevimab at preventing RSV-related emergency department (ED) visits, inpatient hospitalizations, and intensive care unit (ICU) admissions.
DESIGN, SETTING, AND PARTICIPANTS: This test-negative case-control study obtained data from 7 tertiary care pediatric hospitals located in Ontario and Quebec, Canada, that are members of the Surveillance Program for the Rapid Identification and Tracking of Infectious Diseases in Kids (SPRINT-KIDS) Project. Symptomatic infants younger than 12 months who were tested for RSV in the ED, inpatient units, or ICUs of participating institutions between October 27, 2024, and March 1, 2025, were included.
EXPOSURE: Receipt of nirsevimab 7 days or more prior to RSV test date.
MAIN OUTCOME AND MEASURE: The primary outcome was laboratory-confirmed RSV infection. Participants were stratified by disposition outcome-ED visit only, hospitalization, or ICU admission-on the day of specimen collection or within the subsequent 14 days.
RESULTS: Among the 1942 eligible encounters in infants (median [IQR] age, 3.0 [1.9-5.6] months; 1110 males [57.2%]) who were tested for RSV, 683 (35.2%) had RSV-positive test results (cases) and 1259 (64.8%) had RSV-negative test results (controls). Overall, 429 infants (22.1%) received nirsevimab. A lower proportion of cases than controls received nirsevimab (7.0% [48 of 683] vs 30.3% [381 of 1259]; P < .001). Adjusted nirsevimab effectiveness against laboratory-confirmed RSV was estimated to be 78% (95% CI, 68%-84%), including 77% (95% CI, 62%-86%) against ED visits, 79% (95% CI, 66%-87%) against hospitalizations, and 97% (95% CI, 85%-100%) against ICU admissions. Effectiveness remained high across all subgroups, including premature infants (90% [95% CI, 66%-98%]), those with comorbidities (86% [95% CI, 37%-98%]), and time from receipt (85% [95% CI, 75%-92%]); results of sensitivity analyses were consistent with those of primary analysis.
CONCLUSIONS AND RELEVANCE: This test-negative case-control study found that administration of nirsevimab to infants had high estimated effectiveness in preventing RSV disease severity that requires hospital-based care. The results suggest that nirsevimab has the potential to reduce the burden of RSV.
参考来源
- Buchan SA, Xie J, Bhatt M, et al. Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab. JAMA Netw Open. 2026. PMID: 42734914. doi:10.1001/jamanetworkopen.2026.33621
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。